Astrazeneca Pharma India Limited (ASTRAZEN)
ISIN: - Industry: Drug Manufacturers—Specialty & Generic Sector: Healthcare Website
3053.5
-18.5(-0.6%)

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.

Pricing Updates

TODAY'S HIGH

3095

TODAY'S LOW

3043

52 WEEK HIGH

3349

52 WEEK LOW

2445.7

Major Holders

% of Shares Held by
All Insider

82.14%

% of Shares Held by
Institutions

2.99%

% of Float Held by
Institutions

16.74%

Number of Institutions
Holding Shares

20

Company Overview

MARKET CAP

7633.74 Cr.

ETERPRISE VALUE

7234.58 Cr.

NO. OF SHARES

2.50 Cr.

BOOK VALUE

204.556

DIV. YIELD

8%

DEBT

8.63 Cr.

GROSS PROFIT

488.70 Cr.

CASH

448.41 Cr.

REVENUE

805.60 Cr.

REVENUE/SHARE

322.24

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments0169 Cr.-169 Cr.11.68 Cr.
Change To Liabilities9.67 Cr.-31.34 Cr.41.45 Cr.41.04 Cr.
Total cashflows from Investing Activities4.74 Cr.173.03 Cr.-170.80 Cr.4.28 Cr.
Net Borrowings-3.50 Cr.-2.88 Cr.-2.21 Cr.-2.21 Cr.
Total Cash from Financing Activities-9.45 Cr.-8.97 Cr.-6.36 Cr.-6.36 Cr.
Other Liabilities8.55 Cr.26.62 Cr.7.75 Cr.2.08 Cr.
Total Assets0000
Net Income61.59 Cr.93.30 Cr.72.21 Cr.54.45 Cr.
Change in Cash96.08 Cr.268.84 Cr.-89.74 Cr.59.26 Cr.
Effect of Exchange Rate0000
Total Cash from Operating Activities100.79 Cr.104.78 Cr.87.42 Cr.54.98 Cr.
Depreciation16.94 Cr.19.75 Cr.18.58 Cr.14.92 Cr.
Other Cashflows from Investing Activities11.11 Cr.9.32 Cr.11.93 Cr.11.02 Cr.
Dividends Paid-5 Cr.-5 Cr.-2.50 Cr.-2.50 Cr.
Change to Inventory19.57 Cr.5.35 Cr.-47.03 Cr.-4.96 Cr.
Change to Account Receivables-4.90 Cr.-4.58 Cr.-4.83 Cr.-28.35 Cr.
Other Cashflows from Financing Activities-94.72 Lakhs-1.09 Cr.-1.65 Cr.-1.65 Cr.
Change to Net Income-10.65 Cr.-4.32 Cr.-71 Lakhs-24.20 Cr.
Capital Expenditures-9.61 Cr.-7.71 Cr.-14.22 Cr.-18.69 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax83.03 Cr.127.09 Cr.113.97 Cr.72.67 Cr.
Minority InterestNoneNoneNoneNone
Net Income69.22 Cr.116.26 Cr.102.56 Cr.56.57 Cr.
Selling General Administrative280.92 Cr.219.93 Cr.217.99 Cr.202.67 Cr.
Gross Profit493.63 Cr.512.53 Cr.520.17 Cr.490.48 Cr.
Ebit69.22 Cr.116.26 Cr.102.56 Cr.56.57 Cr.
Operating Income69.22 Cr.116.26 Cr.102.56 Cr.56.57 Cr.
Other Operating Expenses122.53 Cr.153.87 Cr.179.46 Cr.212.87 Cr.
Interest Expense-94.72 Lakhs-1.09 Cr.-1.14 Cr.-1.14 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense21.44 Cr.33.79 Cr.41.76 Cr.18.22 Cr.
Total Revenue805.60 Cr.813.56 Cr.831.81 Cr.728.29 Cr.
Total Operating Expenses736.37 Cr.697.30 Cr.729.25 Cr.671.72 Cr.
Cost of Revenue311.96 Cr.301.03 Cr.311.64 Cr.237.81 Cr.
Total Other Income Expense Net13.81 Cr.10.83 Cr.11.41 Cr.16.10 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.61.59 Cr.93.30 Cr.72.21 Cr.54.45 Cr.
Net Income Applicable to Common Shares61.59 Cr.93.30 Cr.72.21 Cr.54.45 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets0000
Capital Surplus0000
Total Liabilities345.16 Cr.318.54 Cr.341.92 Cr.261 Cr.
Stock Holder Equity511.39 Cr.456.17 Cr.364.44 Cr.300.80 Cr.
Minority Interest0000
Other Liabilities140.98 Cr.34.77 Cr.28.24 Cr.21.92 Cr.
Total Assets856.55 Cr.774.71 Cr.706.36 Cr.561.80 Cr.
Common Stock5 Cr.5 Cr.5 Cr.5 Cr.
Retained Earnings0377.23 Cr.285.50 Cr.221.35 Cr.
Other Liabilities7.49 Cr.6.41 Cr.5.38 Cr.2.02 Cr.
Good Will0000
Treasury Stock506.39 Cr.73.94 Cr.73.94 Cr.74.45 Cr.
Other Assets74.18 Cr.70.97 Cr.68.27 Cr.75.35 Cr.
Cash448.45 Cr.352.34 Cr.83.50 Cr.173.24 Cr.
Current Liabilities332.64 Cr.303.50 Cr.327.24 Cr.258.98 Cr.
Long Term Asset Charges16.28 Cr.14.53 Cr.14.64 Cr.23.36 Cr.
Short Long Term Debt0000
Other Stockholder Equity506.39 Cr.73.94 Cr.73.94 Cr.74.45 Cr.
Property Plant Equipment76.70 Cr.84.98 Cr.95.77 Cr.81.73 Cr.
Total Cur. Assets705.66 Cr.618.76 Cr.542.32 Cr.404.72 Cr.
Long Term Investments0000
Net Tangible Assets511.39 Cr.456.17 Cr.364.44 Cr.300.80 Cr.
Short Term Investments00169 Cr.0
Net Receivables98.24 Cr.91.21 Cr.95.58 Cr.86.12 Cr.
Long Term Debt0000
Inventory140.21 Cr.159.80 Cr.165.15 Cr.118.10 Cr.
Accounts Payable188.05 Cr.178.37 Cr.209.72 Cr.168.20 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account